Ceretam 1200 mg Film-Coated Tablet

Country: Malasja

Lingwa: Ingliż

Sors: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Ingredjent attiv:

PIRACETAM

Disponibbli minn:

AV MANUFACTURING SDN.BHD

INN (Isem Internazzjonali):

PIRACETAM

Unitajiet fil-pakkett:

30 Tablets

Manifatturat minn:

AV MANUFACTURING SDN.BHD

Fuljett ta 'informazzjoni

Consumer Medication Information Leaflet (RiMUP)
CERETAM 1200MG FILM-COATED TABLET
Piracetam 1200mg
1
WHAT IS IN THIS LEAFLET
1.
What Ceretam is used for
2.
How Ceretam works
3.
Before you take Ceretam
4.
How to use Ceretam
5.
While you are using Ceretam
6.
Side effects of Ceretam
7.
Storage and Disposal
8.
Product Description
9.
Manufacturer & product
registration holder
10.
Date of revision
1.
WHAT CERETAM IS USED FOR

Treatment of the elderly with some
degree of cerebral functional
impairment such as loss of memory, a
lack of concentration or alertness and
feeling of dizziness.

Ceretam is indicated for patients
suffering from myoclonus of cortical
origin, irrespective of aetiology
(cause) and should be used in
combination with other anti-
myoclonic therapies.
2.
HOW CERETAM WORKS
Ceretam contains active ingredient
Piracetam. Piracetam acts on the brain
and the nervous system and is thought
to protect it against shortness of oxygen.
Ceretam is used in combination with
other medicines to treat myoclonus.
This is a condition causing muscles,
particularly in the arms and legs, to start
jerk or twitch uncontrollably.
3.
BEFORE YOU USE CERETAM
_When you must not use it_

If you are allergic to the active
ingredient piracetam, other
pyrrolidone derivatives or to other
ingredients of Ceretam Tablet

If you have ever had serious kidney
problems.

If you suffer from Huntington’s
Chorea (an inherited disease that
causes progressive breakdown of
nerve cells in the brain which causes
involuntary movements).

If you have ever experienced a brain
haemorrhage(bleeding).
_-Before you start to use it_
Check with your doctor

If you think your kidney may not be
working perfectly

You have ever had any kind of
bleeding problem.
_-Taking another medicines_
Tell your doctor or pharmacist if you
are taking any other medicines,
including any that you buy without a
prescription from a pharmacy,
supermarket or health food shop:

Thyroid hormones

Acenocoumarol

Antiepileptic drugs

Alcohol

Any

Karatteristiċi tal-prodott

CERETAM 1200MG FILM-COATED TABLET
DESCRIPTION: CERETAM 1200MG FILM-COATED TABLET: Each Ceretam tablet contains
piracetam 1200 mg. It is a white to off- white, oblong shaped, film-coated tablet with CT logo and embossed
line on both sides of the tablet.
PHARMACODYNAMICS:
Pharmacotherapeutic group: Nootropics, ATC code: N06B X03
Mechanism of action:Piracetam's mode of action in cortical myoclonus
is as yet unknown.
Pharmacodynamic effects: Piracetam exerts its haemorrheological
effects on the platelets, red blood cells, and
vessel walls by increasing erythrocyte deformability and by decreasing
platelet aggregation, erythrocyte adhesion
to vessel walls and capillary vasospasm.
- Effects on the red blood cells:In patients with sickle cell anaemia,
piracetam improves the deformability of the
erythrocyte membrane, decreases blood viscosity, and prevents rouleaux
formation.
- Effects on platelets: In healthy volunteers and in patients with
Raynaud's phenomenon, increasing doses of
piracetam up to 12 g was associated with a dose-dependent reduction in
platelet functions compared with pre-
treatment values (tests of aggregation induced by ADP, collagen,
epinephrine and ßTG release), without significant
change in platelet count. Piracetam prolonged bleeding time.
- Effects on blood vessels: In animal studies, piracetam inhibited
vasospasm and counteracted the effects of various
spasmogenic agents. It lacked any vasodilatory action and did not
induce “steal” phenomenon, nor low or no
reflow, nor hypotensive effects.
In healthy volunteers, piracetam reduced the adhesion of RBCs to
vascular endothelium and possessed also a direct
stimulant effect on prostacycline synthesis in healthy endothelium.
-Effects on coagulation factors:In healthy volunteers, compared with
pre-treatment values, piracetam up to 9.6 g
reduced plasma levels of fibrinogen and von Willebrand's factors (VIII
: C; VIII R : AG; VIII R : vW) by 30 to 40
%, and increased bleeding time.
In patients with both primary and secondary Raynaud phenomenon,
compare